Acquisition by Watanabe Todd Franklin of 116100 shares of Arcutis BiotherapeuticsI subject to Rule 16b-3
| ARQT Stock | USD 12.68 1.07 7.78% |
Slightly above 61% of Arcutis Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Arcutis Biotherapeutics suggests that many traders are alarmed. Arcutis Biotherapeutics' investing sentiment can be driven by a variety of factors including economic data, Arcutis Biotherapeutics' earnings reports, geopolitical events, and overall market trends.
Arcutis |
Filed transaction by Arcutis BiotherapeuticsInc Director, Officer See Remarks. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Arcutis Biotherapeutics Fundamental Analysis
We analyze Arcutis Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Arcutis Biotherapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Arcutis Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arcutis Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Arcutis Biotherapeutics Related Equities
| XFOR | X4 Pharmaceuticals | 10.87 | ||||
| SPRO | Spero Therapeutics | 9.64 | ||||
| DSGN | Design Therapeutics | 6.75 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.86 | ||||
| ABOS | Acumen Pharmaceuticals | 2.48 | ||||
| MIRM | Mirum Pharmaceuticals | 2.44 | ||||
| DAWN | Day One | 1.13 | ||||
| APLS | Apellis Pharmaceuticals | 0.71 | ||||
| ERAS | Erasca | 0.54 | ||||
| INZY | Inozyme Pharma | 1.45 | ||||
| TERN | Terns Pharmaceuticals | 1.56 | ||||
| GLUE | Monte Rosa | 1.74 | ||||
| BOLT | Bolt Biotherapeutics | 1.92 | ||||
| CHRS | Coherus BioSciences | 2.11 |
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.